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BackgroundzzLipoid proteinosis (LP) is a rare autosomal recessive disorder characterized by 
a hoarse voice, variable scarring, and infiltration of the skin and mucosa. This disease is associ-
ated with mutations of the gene encoding extracellular matrix protein 1 (ECM1).
Case ReportzzThis was a clinical and molecular study of a new case of LP with a severe phe-
notype. A 35-year-old female born to nonconsanguineous parents developed dermatological 
and extracutaneous symptoms in her 9th month of life. The neurological abnormalities of the 
disease began to appear at the age of 19 years. Computed tomography revealed cranial calcifi-
cations.
ConclusionszzThe diagnosis of LP was confirmed by histopathological findings and direct se-
quencing of ECM1. A new homozygous nonsense mutation was identified in exon 7 of ECM1, 
c.1076G>A (p.Trp359*). This mutation was not detected in 106 chromosomes of healthy individ-
uals with a similar demographic origin. Microsatellite markers around ECM1 were used to con-
struct the haplotype in both the parents and the patient. Reports on genotype-phenotype correla-
tions in LP point to a milder phenotype in carriers of missense mutations in the Ecm1a isoform, 
whereas mutations in the Ecm1b isoform are thought to be associated with more severe pheno-
types. The present findings in a Spanish patient carrying a truncating mutation in exon 7 revealed 
complete dermatological and neurological manifestations. J Clin Neurol 2014;10:64-68
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Introduction
Lipoid proteinosis (LP; OMIM 247100), also known as Ur-
bach-Wiethe disease, is a rare autosomal recessive disorder 
characterized by variable scarring and infiltration of the skin 
and mucosa. Clinical features include warty skin infiltration, 
papules on the eyelids, and skin scarring, in addition to extra-
cutaneous abnormalities such as hoarseness of the voice, epi-
lepsy, and neuropsychiatric abnormalities.1 In severe cases this 
infiltration can lead to respiratory obstruction. Histological ex-
aminations reveal the widespread deposition of hyaline mate-
rial and disruption of the basement membrane around blood 
vessels and at the dermal-epidermal junction.
The molecular basis of LP has been elucidated: it appears to 
result from mutations in the gene encoding extracellular ma-
trix protein 1 (Ecm1, ECM1; OMIM 602201).2 Ecm1 is a key 
protein in epidermal differentiation, binding of dermal colla-
gens and proteoglycans, and regulation of angiogenesis. Ho-
mozygous and compound heterozygous mutations in ECM1 
have previously been described in patients with LP. ECM1 
maps to chromosome 1q21.2, and there are three known 
splice variants (Ecm1a, Ecm1b, and Ecm1c) and a putative 
fourth variant.2,3 Ecm1a is the most widely expressed splice 
variant, while Ecm1b has a much more restricted expression 
pattern.4 Ecm1 contains numerous cysteine residues that are 
arranged in a specific manner. The cysteine-containing do-
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mains all have the typical CC-(X7-10)-C arrangement that is 
capable of the forming protein double loops involved in pro-
tein-protein interactions.5 Therefore, Ecm1 and its alternative 
splicing isoforms may serve as binding and transport proteins 
in epidermal differentiation.6 Ecm1 was found to negatively 
regulate endochondral bone formation by inhibiting alkaline 
phosphatase activity and mineralization.7,8
This report describes the case of an LP patient who carries 
a homozygous, undescribed nucleotide transition in exon 7 of 
ECM1 causing a homozygous nonsense mutation. Her clini-
cal, histological, and molecular features indicate that the trun-
cating mutation of exon 7 causes a severe phenotype.
Case Report
Patients
The index patient was a 35-year-old woman born to unrelated 
parents who developed a progressively hoarse voice from 9 
months of age, and vesicular and bullous lesions that appeared 
after minimal trauma. A physical examination revealed depo-
sition of hyaline material in the larynx, epidermolysis bullosa, 
multiple yellowish warty skin papules on the body, and diffuse 
acneiform scars over her face, with blisters in the mouth, eyes, 
and areas subject to friction. Neurological symptoms included 
unilateral paresthesia, dizziness, and memory loss associated 
with depression, in addition to a decline in verbal fluency and 
impaired coordination of movement from the age of 19 years. 
Computed tomography revealed bilateral and symmetric amyg-
daloid-uncal calcifications (Fig. 1A and B). Gradient refo-
cused-echo T2*-weighted MRI images (Fig. 1C and D) re-
vealed marked hypointense bilateral rounded symmetric 
lesions in the mesial temporal lobes, involving the amygdaloid 
complex. A routine EEG (awake and sleep) recording was 
slightly unstable, but no epileptiform activity was evident. A 
cognitive event-related potential P-300 wave revealed a reac-
tion-time delay during development of the Posner task, with a 
normal latency of the P3 component during the oddball task. 
The results of a neurological examination were unremark-
Fig. 1. A and B: Axial brain computed tomography image showing bilateral and symmetric calcifications of the mesial temporal lobes (amyg-
dala complex, uncinate, hippocampi, and parahippocampal giri). C: Axial brain GRE T2*-weighted MRI image (TR; TE) depicting bilaterally 
hypointense lesions in both amygdaloid bodies. D: Coronal brain T2*-weighted MRI image showing the same horn-shaped amygdaloid le-
sions. E: Homogeneous eosinophilic material was deposited around the sweat coils and capillaries, with the perineurium of a nerve also 
being affected (hematoxylin and eosin stain, ×200). F: The deposited material stained very strongly with periodic acid Schiff (diastase-resis-
tant; ×200).
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able, and a neuropsychological evaluation revealed a de-
crease in information processing speed and disturbances in 
episodic memory and the amnesic evocation process. These 
findings could be explained by her depressed mood. The re-
sults of a blood workup were unremarkable.
A skin biopsy (Fig. 1E and F) of the granuloma annulare 
revealed sweat glands and small nerves with deposition of 
strongly periodic-acid-Schiff-positive homogeneous, eosino-
philic, hyaline-like material and diastase resistant granules 
around dermal blood vessels, revealing its glycoproteic nature, 
which is consistent with LP.
Sequencing of the coding region of ECM1
Genomic DNA was purified from blood samples using a salt-
ing-out procedure, and stored in TE buffer. ECM1 was ampli-
fied by a polymerase chain reaction (PCR) with primers span-
ning all ten exons and intronic flanking regions. Genomic 
DNA (100 ng) was amplified in 20-μL reaction volumes con-
taining 20 pmol of primers (Table 1), 1.5 nmol of MgCl2, 4 
nmol of dNTP, and 1 U of AmpliTaq DNA polymerase (Ap-
plied Biosystems, Warrington, UK). The PCR products were 
separated by 1.5%-agarose-gel electrophoresis and purified 
with the Qiaquick Gel Extraction Kit (Qiagen, Crawley, UK). 
Amplified fragments were run and sequenced in an ABI 3130 
genetic analyzer.
Sequencing of exon 7 revealed the presence of a single 
base substitution at position 1076 of cDNA (GenBank acces-
sion no. NM_004425.3). The c.1076G>A transversion causes 
a premature termination codon, p.Trp359*, that affects the 
Ecm1a isoform. The patient was found to be homozygous for 
the mutation, while her parents were heterozygous carriers (Fig. 
2). No other changes or polymorphisms were found in the 
ECM1 coding region. The mutation causes the loss of a restric-
tion target for NlaIII endonuclease, which was therefore used 
as a screening test. The mutation was not present in 106 
chromosomes of unrelated control subjects.
Haplotype study
Four different polymorphic dinucleotide microsatellites were 
analyzed in this study: D1S2344, D1S2345, D1S305, and 
D1S2624. The primer sequences were obtained from the 
uniSTS database of the National Center for Biotechnology 
Information. The sizes of the microsatellites were determined 
by direct sequencing in the ABI 3130 genetic analyzer.
The four markers allowed determination of the segregation 
phase and the haplotypes associated with the c.1076G>A trans-
version. The parents’ haplotypes differed significantly in the 
mutated chromosomes, although double recombination events 
cannot be ruled out (Fig. 2).
Discussion
Lipoid proteinosis was first described in 1929, but the current 
literature still contains only around 300 published cases. A 
Spanish patient carrier of a homozygous mutation (c.1076G>A) 
ECM1 has been described herein. A previous report5 described 
a different mutation in two Caucasian brothers (c.1077G>A). 
Nonetheless, the same stop codon, W359X, predicts a truncat-
ed protein in both cases. Reports on the genotype-phenotype 
relationship point to a milder phenotype in carriers of mis-
sense mutations in the Ecm1a isoform, whereas mutations in 
the Ecm1b isoform (i.e., with exon-7 skipping) have been as-
sociated with more severe phenotypes.9 This is in agreement 
with the present finding in a Spanish patient carrying a trun-
cating mutation in exon 7 and exhibiting a complete dermato-
logical and neurological manifestation. It is difficult to study 
the genotype-phenotype correlation because of the different 
ages of patients, since many clinical features vary with age. 
The patient studied herein reported spontaneous hemorrhagic 
blisters under both humid and very dry environmental condi-
tions, which suggests that both genetic and environmental 
factors can modify the disease severity. Therefore, genotype-
phenotype differences among reports can be at least partially 
attributed to age and nongenetic factors that differentially af-
fect the development of neurologic symptoms and the sever-
Table 1. Primers used for sequencing ECM1
Exon Forward primer Reverse primer
Annealing 
temperature (ºC)
PCR product 
size (bp)
Exon 1 AGCAGCTGGGACTGAGTCAT TGCTAGTGATGAGCCGTCTG 61 350
Exon 2, 3 CCTGACTTGCCCTTCTTCC CTCTTCCCTCCTTTCCACCT 60 347
Exon 4, 5 CAGTGACCCTCCAGGTTTCT CAGAGCCCACCGTCTTGTCT 60 484
Exon 6 CACTGTTTTCCCCATTCCAG GGCATCAAGAACCCAACCT 60 365
Exon 7 CTGATCCTCCCCTCTTGCTC CAGGCAAACAGGCTCTCAG 61 439
Exon 8 AGGAGAGAAGGGGCCAAGT TAGGGTCTTTGGGCATCTTC 61 400
Exon 9 AGTTGCCTAGTCCTTCCCCA AGGCCAGGTCAGAGTGAAGA 60 408
Exon 10 GGCACCCAAGTATCTACATCTG CCAAATCCAAGAGGTGTTTAGTG 61 399
PCR: polymerase chain reaction.
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ity of this disease.
Extracellular matrix protein 1 has specific binding sites for 
several extracellular matrix proteins and polysaccharides: 1) 
the NH2-terminal free cysteine domain can bind collagen IV 
[amino acids (aa) 14-207]; 2) the tandem repeat can bind fib-
ulin 1C/1D, matrix metalloproteinase 9 (MMP-9), and lam-
inin (aa 207-361); 3) the C-terminal region can interact with 
domain V of perlecan (aa 424-540); and 4) Ecm1 promotes 
the link between collagen IV and laminin.6,10-12 Moreover, 
Sercu et al.12 suggested that Ecm1 can act as a “biological 
glue” in the skin’s basement membrane to maintain the struc-
tural and functional integrity of this organ. If translated, the 
stop codon described in the present Spanish patient predicts a 
truncated protein that would impair the interaction with per-
lecan, MMP-9, fibulin, and laminin. Given the lack of symp-
toms in the carrier parents, haploinsufficiency or toxic effects 
could be discarded as pathogenic mechanisms. Extracutaneous 
manifestations such as epilepsy and neuropsychiatric disor-
ders13,14 can be related to the inhibition by Ecm1 of MMP-9 ac-
tivity,10 a protein that is strongly expressed in the brain.15 The 
truncated 358 polypeptide lacks regulatory MMP-9 activity 
and the aforementioned binding domains to several other 
matrix components, and therefore causes impairment of the 
extracellular matrix structure. The histological images obtained 
in this study clearly showed material deposition around sweat 
coils and capillaries.
A new mutation in exon 7 of ECM1 is described herein that 
leads to a premature termination codon as the cause of a se-
vere phenotype of LP. The lack of coincidence in the parents’ 
haplotypes is noteworthy, although a recombination among the 
microsatellite markers cannot be ruled out. In conclusion, the 
identification of pathogenic mutations in ECM1 is significant 
for genetic counseling with respect to clinical severity and 
prognosis.
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